GSK files for new Synflorix use in EU; Australian activists lobby for doc-payment disclosure;

 @FiercePharma: Sunshine in Australia? Critics call for disclosure of pharma payments to individual docs. Report | Follow @FiercePharma

> GlaxoSmithKline ($GSK) asked European regulators to approve a new use for its pneumococcal vaccine, Synflorix, to prevent pneumonia in infants and small children. Report

> Australian public health advocates are lobbying for drugmakers to disclose payments to individual doctors, rather than report payment totals as rules now require. Report

> Bayer's supervisory board officially elected former CEO Werner Wenning as chairman, after a shareholder's election in April. Report

> Japan's Mitsui plans to snap up another 25% stake in the pharmaceutical ingredient maker Arch Pharmalabs, increasing its overall position in the Indian company to 30%. Report

> Reckitt Benckiser tapped Smith & Nephew's Adrian Hennah as its new chief financial officer, counting on Hennah's healthcare experience to help it expand its health brands. Report

> UCB inaugurated its new 65 million euro biotech plant in Belgium, where it plans to turn out antibody-based therapies for clinical studies and develop full-scale manufacturing processes. Report

Medical Device News

 @FierceMedDev: Life Technologies and Bristol-Myers Squibb are partnering to develop companion Dx. Who's next? Release | Follow @FierceMedDev

 @MarkHFierce: With all the problems metal hip implants are causing, some good news: at least they don't appear to trigger cancer. Report | Follow @MarkHFierce

 @DamianFierce: Danaher Corp. is spending $338M to pick up Dx company Iris International. News | Follow @DamianFierce

> Life Technologies reels in Bristol-Myers Squibb as companion Dx partner. Article

> Trouble thinking? There may be a brain implant for that. Item

Biotech News

 @FierceBiotech: Little NovaDigm races Pfizer, Glaxo in race to develop MRSA vaccines. Item | Follow @FierceBiotech

 @JohnCFierce: Targacept sharpens well-used budget ax after another drug flames out. More | Follow @JohnCFierce

 @RyanMFierce: Wow. China's BGI buying rival DNA sequencing outfit Complete Genomics for $3.15 per share (value $117.6M). Release | Follow @RyanMFierce

> Sanofi workers plan protests as execs prep for big job cuts next week. Article

> Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers of recklessness. Story

> Threshold shares slammed after lead cancer drug trips on survival goal. News

CRO News

> Pfizer launches joint venture with Chinese API maker. Story

> Patheon lifts profit outlook after strong quarter. News

> INC expands clinical ops in South Korea. Article

> Quintiles signs on to sell Sinclair IS drugs in Mexico. More

Biotech IT News

> Boehringer Ingelheim debuts pharma game 'Syrum' on Facebook. Article

> Pfizer taps cloud computing to gain control of supply chain. Story

> Illumina partners with Partners HealthCare to combine sequencing and software. Report

And Finally ... Cost-cutting in China is spawning violent attacks against hospital doctors and other healthcare workers. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.